The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening
Open accessAbstract
Despite the urgent need for new antitubercular drugs, few are on the horizon. To combat the problem of emerging drug resistance, structurally unique chemical entities that inhibit new targets will be required. Here we describe our investigations using whole cell screening of a diverse collection of small molecules as a methodology for identifying novel inhibitors that target new pathways for Mycobacterium tuberculosis drug discovery. We find that conducting primary screens using model mycobacterial species may limit the potential for identifying new inhibitors with efficacy against M. tuberculosis. In addition, we confirm the importance of developing in vitro assay conditions that are reflective of in vivo biology for maximizing the proportion of hits from whole cell screening that are likely to have activity in vivo. Finally, we describe the identification and characterization of two novel inhibitors that target steps in M. tuberculosis cell wall biosynthesis. The first is a novel benzimidazole that targets mycobacterial membrane protein large 3 (MmpL3), a proposed transporter for cell wall mycolic acids. The second is a nitro-triazole that inhibits decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1), an epimerase required for cell wall biosynthesis. These proteins are both among the small number of new targets that have been identified by forward chemical genetics using resistance generation coupled with genome sequencing. This suggests that methodologies currently employed for screening and target identification may lead to a bias in target discovery and that alternative methods should be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice
Cox, J. S., Chen, B., McNeil, M., & Jacobs, W. R. (1999) · Nature · doi:10.1038/47042 · Cited by 745
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Singh, R., Manjunatha, U., Boshoff, H. I. M., Ha, Y. H., Niyomrattanakit, P., Ledwidge, R., Dowd, C. S., Lee, I. Y., Kim, P., Zhang, L., et al. (2008) · Science · doi:10.1126/science.1164571 · Cited by 628
Self-citationBreeding latitude drives individual schedules in a trans-hemispheric migrant bird
Conklin, J. R., Battley, P. F., Potter, M. A., & Fox, J. W. (2010) · Nature Communications · doi:10.1038/ncomms1072 · Cited by 582
Tahlan, K., Wilson, R., Kastrinsky, D. B., Arora, K., Nair, V., Fischer, E., Barnes, S. W., Walker, J. R., Alland, D., Barry, C. E., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05708-11 · Cited by 504
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442
Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor
Ehrt, S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni013 · Cited by 383
Global tuberculosis drug development pipeline: the need and the reality
Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J., & Wang, X. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-9 · Cited by 374
Cited by
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
The Mycobacterial Cell Wall—Peptidoglycan and Arabinogalactan
Alderwick, L. J., Harrison, J., Lloyd, G. S., & Birch, H. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021113 · Cited by 265
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target
Zhang, B., Li, J., Yang, X., Wu, L., Zhang, J., Yang, Y., Zhao, Y., Zhang, L., Yang, X., Yang, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.003 · Cited by 263
Self-citationStanley, S. A., Barczak, A. K., Silvis, M. R., Luo, S. S., Sogi, K., Vokes, M., Bray, M.-A., Carpenter, A. E., Moore, C. B., Siddiqi, N., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003946 · Cited by 251
Self-citationLi, W., Upadhyay, A., Fontes, F. L., North, E. J., Wang, Y., Crans, D. C., Grzegorzewicz, A. E., Jones, V., Franzblau, S. G., Lee, R. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03229-14 · Cited by 202
MmpL3 is the flippase for mycolic acids in mycobacteria
Xu, Z., Meshcheryakov, V. A., Poce, G., & Chng, S.-S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700062114 · Cited by 201
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1
Rybniker, J., Vocat, A., Sala, C., Busso, P., Pojer, F., Benjak, A., & Cole, S. T. (2015) · Nature Communications · doi:10.1038/ncomms8659 · Cited by 191
Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052951 · Cited by 177
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Direct Inhibition of MmpL3 by Novel Antitubercular Compounds
Li, W., Stevens, C. M., Pandya, A. N., Darzynkiewicz, Z., Bhattarai, P., Tong, W., Gonzalez-Juarrero, M., North, E. J., Zgurskaya, H. I., & Jackson, M. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00048 · Cited by 97
Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic target
Adams, O., Deme, J. C., Parker, J. L., Fowler, P. W., Lea, S. M., & Newstead, S. (2021) · Structure · doi:10.1016/j.str.2021.06.013 · Cited by 63
Insights on How the Mycobacterium Tuberculosis Heme Uptake Pathway can Be Used as a Drug Target
Owens, C. P., Chim, N., & Goulding, C. W. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.109 · Cited by 50
Gao, C., Peng, C., Shi, Y., You, X., Ran, K., Xiong, L., Ye, T.-H., Zhang, L., Wang, N., Zhu, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep29717 · Cited by 48
Self-citation
Metadata
- Authors
- Stanley, S. A., Grant, S. S., Kawate, T., Iwase, N., Shimizu, M., Wivagg, C., Silvis, M., Kazyanskaya, E., Aquadro, J., Golas, A., Fitzgerald, M., Dai, H., Zhang, L., & Hung, D. T.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-05-21
- Volume
- 7
- Issue
- 8
- Pages
- 1377-1384
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W1986288809
- Cited by
- 253
- References
- 26
- FWCI
- 18.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
